Cargando…
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727296/ https://www.ncbi.nlm.nih.gov/pubmed/34148055 http://dx.doi.org/10.1038/s41375-021-01322-1 |
| _version_ | 1784626492632727552 |
|---|---|
| author | Pepper, Andrea G. S. Zucchetto, Antonella Norris, Kevin Tissino, Erika Polesel, Jerry Soe, Zarni Allsup, David Hockaday, Anna Ow, Pei Loo Hillmen, Peter Rawstron, Andrew Catovsky, Daniel Bulian, Pietro Bomben, Riccardo Baird, Duncan M. Fegan, Christopher D. Gattei, Valter Pepper, Chris |
| author_facet | Pepper, Andrea G. S. Zucchetto, Antonella Norris, Kevin Tissino, Erika Polesel, Jerry Soe, Zarni Allsup, David Hockaday, Anna Ow, Pei Loo Hillmen, Peter Rawstron, Andrew Catovsky, Daniel Bulian, Pietro Bomben, Riccardo Baird, Duncan M. Fegan, Christopher D. Gattei, Valter Pepper, Chris |
| author_sort | Pepper, Andrea G. S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8727296 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87272962022-01-18 Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies Pepper, Andrea G. S. Zucchetto, Antonella Norris, Kevin Tissino, Erika Polesel, Jerry Soe, Zarni Allsup, David Hockaday, Anna Ow, Pei Loo Hillmen, Peter Rawstron, Andrew Catovsky, Daniel Bulian, Pietro Bomben, Riccardo Baird, Duncan M. Fegan, Christopher D. Gattei, Valter Pepper, Chris Leukemia Letter Nature Publishing Group UK 2021-06-19 2022 /pmc/articles/PMC8727296/ /pubmed/34148055 http://dx.doi.org/10.1038/s41375-021-01322-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Pepper, Andrea G. S. Zucchetto, Antonella Norris, Kevin Tissino, Erika Polesel, Jerry Soe, Zarni Allsup, David Hockaday, Anna Ow, Pei Loo Hillmen, Peter Rawstron, Andrew Catovsky, Daniel Bulian, Pietro Bomben, Riccardo Baird, Duncan M. Fegan, Christopher D. Gattei, Valter Pepper, Chris Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies |
| title | Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies |
| title_full | Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies |
| title_fullStr | Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies |
| title_full_unstemmed | Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies |
| title_short | Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies |
| title_sort | combined analysis of ighv mutations, telomere length and cd49d identifies long-term progression-free survivors in tp53 wild-type cll treated with fcr-based therapies |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727296/ https://www.ncbi.nlm.nih.gov/pubmed/34148055 http://dx.doi.org/10.1038/s41375-021-01322-1 |
| work_keys_str_mv | AT pepperandreags combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT zucchettoantonella combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT norriskevin combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT tissinoerika combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT poleseljerry combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT soezarni combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT allsupdavid combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT hockadayanna combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT owpeiloo combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT hillmenpeter combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT rawstronandrew combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT catovskydaniel combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT bulianpietro combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT bombenriccardo combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT bairdduncanm combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT feganchristopherd combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT gatteivalter combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies AT pepperchris combinedanalysisofighvmutationstelomerelengthandcd49didentifieslongtermprogressionfreesurvivorsintp53wildtypeclltreatedwithfcrbasedtherapies |